Oligodendrocytes in a dish for the drug discovery pipeline: the risk of oversimplification
Vito Antonio Baldassarro1
Luciana Giardino2
Laura Calzà3
1.Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Bologna, Italy2.Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Bologna, Italy;Department of Veterinary Medical Sciences, University of Bologna;IRET Foundation, Bologna, Italy3.Health Science and Technologies Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Bologna, Italy;Department of Pharmacy and Biotechnology, University of Bologna;Montecatone Rehabilitation Institute, Bologna, Italy
摘要：Myelination, remyelination and demyelination: modeling the in vitro drug discovery pipeline: Demyelination is a multifactorial event occurring in diseases primarily involving myelin forming cells (oligodendrocytes, OLs) and their precursors (oligodendrocyte precursor cells, OPCs) such as multiple sclerosis, but is also involved in the pathology of other central nervous system (CNS) injuries and diseases, such as neonatal encephalopathy, brain and spinal cord injury, and Alzheimer's disease. In numerous conditions, myelin repair occurs spontaneously, leading to anatomical and functional restitution. Many pathological mechanisms, however, may interfere with both developmental myelination, which occurs during late gestation and post-natal periods, and myelin replacement/repair (remyelination) which occurs in the adult CNS (Butt et al., 2019), and which can lead to the failure of myelination/remyelination. Improvement of endogenous myelin forming/repair capability is currently a recognized therapeutic target in demyelinating injuries and diseases.
机标关键词：
论文发表日期：2021-02-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 291-293 )